Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In Process Receivables - Net Shares Issued Shares Outstanding Shares Outstanding Shares Repurchased

Tandem Diabetes Care (TNDM) Long-Term Debt Repayments (2024 - 2025)

Tandem Diabetes Care filings provide 3 years of Long-Term Debt Repayments readings, the most recent being -$40.8 million for Q4 2025.

On a quarterly basis, Long-Term Debt Repayments changed N/A to -$40.8 million in Q4 2025 year-over-year; TTM through Sep 2025 was $40.8 million, a N/A change, with the full-year FY2018 number at $87.7 million, changed N/A from a year prior.
Long-Term Debt Repayments hit -$40.8 million in Q4 2025 for Tandem Diabetes Care, down from $40.8 million in the prior quarter.
In the past five years, Long-Term Debt Repayments ranged from a high of $246.1 million in Q1 2024 to a low of -$246.1 million in Q3 2024.